Cite
Brem EA, Li H, Beaven AW, et al. SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool. J Geriatr Oncol. 2021;doi: 10.1016/j.jgo.2021.10.003.
Brem, E. A., Li, H., Beaven, A. W., Caimi, P. F., Cerchietti, L., Alizadeh, A. A., Olin, R., Henry, N. L., Dillon, H., Little, R. F., Laubach, C., LeBlanc, M., Friedberg, J. W., & Smith, S. M. (2021). SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool. Journal of geriatric oncology, . https://doi.org/10.1016/j.jgo.2021.10.003
Brem, Elizabeth A, et al. "SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool." Journal of geriatric oncology vol. (2021). doi: https://doi.org/10.1016/j.jgo.2021.10.003
Brem EA, Li H, Beaven AW, Caimi PF, Cerchietti L, Alizadeh AA, Olin R, Henry NL, Dillon H, Little RF, Laubach C, LeBlanc M, Friedberg JW, Smith SM. SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool. J Geriatr Oncol. 2021 Oct 19; doi: 10.1016/j.jgo.2021.10.003. Epub 2021 Oct 19. PMID: 34686472.
Copy
Download .nbib